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Abstract
Background: Probiotic lactic acid bacteria (LAB) support a functional and balanced immune system, and
contribute to immune modulatory effects in combatting microbial pathogens, including viruses. Most cervical
cancers are associated with anogenital region infection with high-risk (HR) human papillomavirus (HPV). In this
study, we analyzed the antiviral activity of Bifidobacterium adolescentis SPM1005-A in the SiHa cervical cancer cell
line expressing HPV type 16.
Methods: We assessed the cellular toxicity of B. adolescentis SPM1005-A in SiHa cells by the Trypan blue dye
exclusion assay. Cells (3.6 × 105) in culture plates with or without B. adolescentis SPM1005-A in the same type of
medium, were incubated with HPV type 16 at a concentration of 5.1 × 107 cfu/ml. For antiviral analysis, we
performed quantitative real-time PCR (qRT-PCR) for E6 and E7 oncogene expressions and observed protein levels
by immunoblotting.
Results: The qRT-PCR results showed that E6 and E7 mRNA levels decreased simultaneously. Western blot analysis
revealed that the E6 protein expression slightly decreased after 24 and 48 h, but the level of E7 protein expression
appear unaffected compared with that in the control. Decreased HPV16 E6 and E7 mRNA transcript and protein
levels were not associated with cell morphology or significant cytotoxic effects.
Conclusions: This study showed that B. adolescentis SPM1005-A had antiviral activity through suppression E6 and
E7 oncogene expression. The results suggest that B. adolescentis SPM1005-A could be potential applications of
HPV-associated cervical cancer prevention.
Keywords: antiviral activity, Bifidobacterium adolescentis SPM1005-A, human papillomavirus (HPV) type 16, quantita-
tive real-time PCR (qRT-PCR)
Background
Cervical cancer is the second most common malignant
disease of the female reproductive organs, with an inci-
dence per year of almost half a million and a mortality
rate of approximately 25% [1]. Most cervical cancers are
associated with the anogenital region or mucosa cell
infection with human papillomavirus (HPV) [2]. Of the
more than 200 different HPV types identified, 30 HPV
types infect the anogenital skin and oral mucosa and can
be further classified as low risk (LR) or high risk (HR)
based on the clinical prognosis of their associated lesions
[3]. Approximately 99.7% of cervical cancers contain viral
DNA of HR types, with type 16 being the most prevalent,
followed by types 18, 31, 33 and 45 [4]. The malignant
phenotype of HR types depends on the expression of two
viral genes E6 and E7, which bind to p53 and retinoblas-
toma protein (pRb) and neutralize their function, respec-
tively [5]. The most important function of E6 protein is
binding of the tumor suppressor p53, which leads to it
degradation through an ubiquitin proteolytic pathway.
Degradation of p53 bypasses the normal growth arrest
signals at the G1/S and G2/M checkpoints and is the
major cause of chromosomal instability, with mutational
consequences for HPV-positive cells [6]. The E7 protein
interacts with pRb and releases transcription factor E2F,
which induces expression of genes involved in cellular
differentiation and proliferation [7,8]. Therefore, the
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studies for inhibitors of the oncogenic proteins E6 and E7
of HPV type 16 are constantly in progress.
Lactic acid bacteria (LAB) are widely used and gener-
ally recognized as safe organisms for animal and human
applications. They produce antimicrobial substances such
as organic acids, hydrogen peroxide, diacetyl and bacter-
iocins, which have beneficial effects on the host organ-
isms [9]. Probiotic LAB support functional and balanced
immune systems and contribute to immune modulatory
effects in combatting microbial pathogens, including
viruses [10]. Several studies have reported that LAB such
as Lactobacilli boost the antiviral effect against human
rotaviruses that cause diarrhea, human immunodefi-
ciency virus type 1 and influenza virus [11-13].
Among commensal bacteria, Bifidobacteria is one of
the most numerous probiotics in the mammalian gut
that belong to LAB [14]. Xiao et al. have reported choles-
terol reduction by a supplement containing Bifidobacter-
ium longum, and Le Leu et al. reported the potential of
Bifidobacterium animalis subspecies Lactis to prevent
colorectal cancer. Also, antitumor activity has been stu-
died in peptidoglycans isolated from a Bifidobacterium
infantis strain [15-17]. Despite the various literatures
indicating a protective effect of Bifidobacteria in epide-
miological studies, the antiviral effects have not yet been
studied in detail. We therefore assessed the antiviral
activity of B. adolescentis SPM1005-A on E6 and E7
mRNA transcript and protein levels in the SiHa cervical
cancer cell line expressing HPV type 16 in vitro.
Methods
Preparation of B. adolescentis SPM1005-A
For the isolation of Bifidobacteria, fecal samples were col-
lected from healthy Koreans (aged 20 to 30 years old) by
BD BBLanaerobic sample collection and transport system
(Becton Dickinson and Co, USA) to maintain anaerobic
conditions. Fecal samples were serially diluted tenfold
from 10-1 to 10-8, and 100 μl were spread into selective
blood liver agar (Nissui Pharm, Japan) containing 5%
sheep blood. After 48 h of incubation in anaerobic condi-
tions (90% N2, 5% H2, 5% CO2) (Bactron Anaerobic
Chamber, USA) at 37°C, brown or reddish-brown colonies
2 mm to 3 mm in diameter were selected for further iden-
tification [18]. A fructose-6-phosphate phosphoketolase
(F6PPK) test was performed to ensure that the colonies
selected were Bifidobacteria [19]. To identify the isolated
Bifidobacterium spp. at the species level, 16S rRNA
sequencing was performed by Bio leaders (Daejeon,
Korea). We established an N-methyl-N’-nitro-N-nitroso-
guanidine (MNNG)-induced mutant of B. adolescentis
SPM1005, which we named SPM1005-A. B. adolescentis
SPM1005-A, was cultured at 37°C for 48 h on general
anaerobic medium (GAM, Nissui Pharm, Japan) under
anaerobic conditions and then centrifuged at 1,200 rpm
for 15 minutes. The supernatant was separated from the
bacterial cell pellet and filtered using an 0.2-μm syringe fil-
ter (Sartorius Stedim Biotech, Germany). The purified
supernatant was used for further experiments. Written
informed consents were obtained from all volunteer who
provided samples and the protocol was approved by the
Institution Review Board of Office of Research Develop-
ment, Sahmyook University.
Cell culture and treatment
SiHa cervical cancer cells expressing HPV type 16 were
obtained from the American Type Culture Collection
http://www.atcc.org. The cell lines were grown in Mini-
mum essential medium alpha (Gibco) containing 10%
heat-inactivated fetal bovine serum (Sigma, USA), 10,000
U/ml penicillin and 10,000 μg/ml streptomycin in a
humidified incubator at 37°C with 5% CO2. SiHa cells
(1.0 × 105 cells per flask) were incubated for 0, 24, or
48 h in the presence or absence of B. adolescentis
SPM1005-A at a concentration of 5.1 × 107 cfu/ml. After
incubation, the culture medium was removed and the
monolayers were washed with phosphate-buffered saline
(PBS) without phenol red and supplements; the cells
were then immediately used for total protein and RNA
extraction.
Cell viability assay
Cell viability was determined by a Trypan blue dye exclu-
sion assay. Cells (3.6 × 105) in culture plates were incu-
bated overnight, and then the medium was changed to
new medium either with or without B. adolescentis
SPM1005-A at a concentration of 5.1 × 107 cfu/ml, and
incubated for 0, 24, 48, and 72 h. After incubation, each
cell suspension was mixed with an equal volume of 0.3%
Trypan blue solution (Samchun Chemical, Korea).
Finally, cells were observed under a microscope, and liv-
ing cells were counted on hemocytometer. Morphological
changes were observed using an inverted microscope
(Olympus, Japan) at × 400 magnification. Each assay was
performed three times in triplicate and results presented
as % of control.
Reverse transcription and quantitative real-time PCR
(qRT-PCR)
Total RNA was extracted from the cell line using RNeasy
mini Kit (Qiagen, USA) according to the manufacturer’s
recommendation. RNA concentration was quantified by
measuring the absorbance at 260 nm. In order to analyze
the same amount of cDNA in every sample, we performed
reverse transcription as a separate step from PCR. The
mRNA was reverse transcribed into cDNA using oligo-dT
primer and Omniscript reverse transcription kit (Qiagen).
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The cDNA was stored at -20°C or directly used in qRT-
PCR. As growth of HPV-transformed cervical cancer cells
is dependent on sustained viral oncogene E6 and
E7 expression, we investigated the inhibitory effects of
B. adolescentis SPM1005-A on the cervical carcinoma cell
line, SiHa, with quantitative real-time PCR (qRT-PCR),
which is an excellent method for quantitation of viral
DNA [20,21].
qRT-PCR was conducted in a Light Cycler (Roche) sys-
tem and the data were analyzed with Light Cycler software
version 4.5. The quantity of HPV16-E6 and HPV16-E7
transcripts in each sample was standardized to glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) transcript
levels. For absolute quantification, cDNA constructed with
specific binding sites for HPV16 E6 and E7 primers were
used to derive the standard curves. Reactions contained
2 μl each of the cDNA solution, MgCl2, primers and Fast
Start DNA Master SYBR Green I (Qiagen). The primer
sequences used for qRT-PCR of HPV16-E6 were 5’-GAC
CCA GAA AGT TAC CAC AG-3’ (nucleotide 44 to
nucleotide 64) and 5’-CAT AAA TCC CGA AAA GCA
AAG-3’ (nucleotide 153 to nucleotide 173), and of E7
were 5’-GGA GGA GGA TGA AAT AGA TGG-3’
(nucleotide 99 to nucleotide 199) and 5’-TGA GAA CAG
ATG GGG CAC AC-3’ (nucleotide 268 to nucleotide
287). GAPDH was used as internal control with primer
sequences of 5’-CTG CAC CAC CAA CTG CTT AG-3’
(forward) and 5’-TTC TGG GTG GCA GTG ATG-3’
(reverse) [22]. The amplification conditions were initial
incubation at 95°C for 10 minutes, followed by 45 cycles
of 95°C for 10 s, 60°C for 10 s and 72°C for 10 s. Results
were calculated using the ΔΔCT method with cDNA from
all samples as a reference as described previously [23].
Positive and negative controls were included in each
experiment to ensure reproducible results.
Protein electrophoresis and immunoblotting
After 24 or 48 h of treatment, each sample was washed
with PBS and treated with lysis buffer (Thermo, USA).
The samples, containing 30 μg of protein, were suspended
in a 2 × sample buffer (Sigma, USA), boiled for 4 minutes
and resolved on 15% sodium dodecyl sulfate polyacryla-
mide gel electrophoresis (SDS-PAGE) gels. The proteins
were transferred to nitrocellulose membrane (Whatman,
USA), and equal loading was verified with Ponceau S
staining (Sigma). Immunodetection was performed with
HPV16-E6 antibody and HPV16-E7 antibody (Santa Cruz
Biotechnology, USA), followed by incubation with donkey
anti-goat horseradish-peroxidase-conjugated antibody and
detection using enhanced chemiluminescence western
blotting detection reagents (Abfrontier). b-Actin was used
as a normalization standard. Each blot is representative of
three experiments.
Statistical analysis
Results were expressed as mean ± SD. One-tailed Stu-
dent’s t tests were employed whenever individual data
points were compared. Mean values of P < 0.05 were
considered statistically significant.
Results
Effect of B. adolescentis SPM1005-A on morphology
Representative images of the morphological changes
observed after 24, 48, or 72 h are shown in Figure 1.
Compared to control PBS-treated cells, cells exposed to
B. adolescentis SPM1005-A for 72 h slowly shrank in
appearance, but there was no observed difference in 24-h
to 72-h treated cells.
Cytotoxic effects
The cytotoxicity of B. adolescentis SPM1005-A was eval-
uated by Trypan blue dye exclusion assay. Based on the
results of the assay, the cell survival rate decreased
slightly (92, 95, 89%, respectively) with 24-h to 72-h
exposure to 5.1 × 107 cfu/ml B. adolescentis SPM1005-
A (Figure 2). This indicates that B. adolescentis
SPM1005-A does not significantly affect the cytotoxicity
of SiHa cells. Consequently, experiments to assess the
antiviral activity were carried out at this tested concen-
tration in this study.
Inhibition of B. adolescentis SPM1005-A on E6 and E7
expression
For this purpose, total RNA was converted to cDNAs for
E6, E7 and GAPDH as a control by using oligo-dT primer
reverse transcription. The qRT-PCR results showed a
reduction of both genes mRNA transcript levels after incu-
bating the cells with B. adolescentis SPM1005-A for
24 and 48 h (Figure 3A). PBS-treated cells were used as a
control. A reduction in E6 mRNA expression was
observed compared with that in untreated cells after 24 h.
In particular, E6 and E7 expression levels were signifi-
cantly inhibited by B. adolescentis SPM1005-A treatment
for 48 h (*P < 0.05, **P < 0.01).
Western blotting
Western blot analysis revealed that the expression of
both proteins decreased slightly after incubation with B.
adolescentis SPM1005-A (Figure 3B). Inhibition of E6
protein levels was observed at both 24 and 48 h in com-
parison to b-actin. The qRT-PCR results revealed that
E7 mRNA levels decreased after treatment in the SiHa
cell line, whereas the level of E7 protein expression in
cells treated with B. adolescentis SPM1005-A appeared
to be unaffected compared with that in the control. In
this respect, the protein change did not consistently
occur in a time-dependent manner.
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Discussion
Cervical cancer is the second most common malignant
disease of the female and is caused by persistent infection
with HPV. The majority of cases of cervical cancer
develop as squamous cell carcinomas (SCCs) or adeno-
carcinoma [24]. The prevalence of HR HPV infection
among young women is typically around 20% to 40%
depending on geographical region, with the incidence
lowering with age as infections are controlled by the host
immune system [25,26].
Probiotics, particularly Bifidobacteria, are used in fer-
mented food and are widely assumed to be safe. Few
attempts have been made recently to study the potential
benefits of LAB. Lactobacillus rhamnosus GG and
Lactobacillus acidophilus CRL431 are known to inter-
fere with virus-induced pathology indirectly, by favoring
cellular homeostasis, either stimulating innate or adap-
tive immunity [27]. In addition, several studies have
shown that orally delivered probiotics can develop a
mutually advantageous symbiosis with the gastrointest-
inal tract and activate immune systems by the release of
proinflammatory cytokines such as tumor necrosis
factor (TNFa), interleukin (IL)-12, or IL-6, and by pro-
duction of anti-inflammatory cytokines such as trans-
forming growth factor b (TGFb) and IL-10 [28-31].
Some Bifidobacterium species have been reported to
prevent infections by pathogenic bacteria such as
Escherichia coli, Salmonella and Helicobacter pylori
[32-34]. Despite literature indicating the beneficial
effects of Bifidobacteria, the antiviral effects have not
yet been studied in cervical carcinoma cell lines. The
antiviral effects of Bifidobacteria have rarely been stu-
died in cervical cancer cell lines or in vivo, so the mole-
cular mechanisms that underlie these effects need to be
investigated in detail.
In the current study, we assessed the inhibitory effects
on HPV oncogene mRNA and protein expression. As pre-
viously mentioned, the carcinogenesis process of cervical
cancer is associated with the overexpression of the viral
oncogenic proteins E6 and E7 that inactivate the tumor
suppressors, p53 and pRb, block apoptosis, shorten telo-
meres and reduce immune recognition [35]. There have
been several attempts to suppress these two genes typical
to HR-HPV16 and HR-HPV18. Li et al. demonstrated that
Figure 1 Morphological changes by Bifidobacterium adolescentis SPM1005-A treatment in the cervical cancer cell line SiHa. (A)
Phosphate-buffered saline (PBS)-treated SiHa cells were cultured with B. adolescentis SPM1005-A at a concentration of 5.1 × 107 cfu/ml for 24 h
(B), 48 h (C) and 72 h (D). Cells were viewed under a microscope and photographed at × 400.
Figure 2 Effect of Bifidobacterium adolescentis SPM1005-A on
viability of SiHa cells. Cells at a density of 1 × 107 were plated
and grown in the presence (squares) of 5.1 × 107 cfu/ml B.
adolescentis SPM1005-A or absence (diamonds) for 0, 24, 48, and 72
h. After incubation, cells were split and counted by the Trypan blue
dye exclusion assay.
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oncogenic gene downregulation mechanisms that increase
tumor suppressor factors and induce apoptosis may be
employed in cervical cancer cells [36].
Our results showed that B. adolescentis SPM1005-A
can downregulate expression of both genes at both the
mRNA and protein levels in SiHa cells. In particular,
expression of both genes was decreased significantly with
B. adolescentis SPM1005-A treatment for 48 h. In addi-
tion, decreased HPV16 E6 and E7 gene expressions and
protein levels were not associated with cell morphology
and significant cytotoxic effects of B. adolescentis
SPM1005-A in SiHa cells. However, it has been not
determined how B. adolescentis SPM1005-A regulates
the expression of E6 and E7 genes or what is the specific
target region.
Conclusions
In summary, B. adolescentis SPM1005-A was found to
have antiviral activity through suppression of E6 and E7
oncogene expression. The results suggest that B. adoles-
centis SPM1005-A could be useful for prevention of
HPV-associated cervical cancer.
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